Greater than 400 Grail sufferers incorrectly informed they could have most cancers

Worker in a lab
Enlarge / Grail is a subsidiary of Illumina, the world’s greatest gene sequencing firm.


Greater than 400 sufferers who signed as much as take a pioneering oncology detection take a look at developed by US biotech firm Grail obtained faulty letters final month suggesting they could have developed most cancers.

In response to an inner firm doc seen by the Monetary Occasions, 408 sufferers have been incorrectly informed that they had a sign of their blood suggesting they may have most cancers.

Grail mentioned the letters have been despatched “in error” by its telemedicine supplier PWNHealth and that its employees had moved swiftly to contact affected prospects to reassure them their take a look at outcomes have been fallacious.

The incident has generated concern amongst some insurers who’re trialing Galleri, a multi-cancer early detection take a look at that claims to have the ability to spot greater than 50 cancers from a single draw of blood.

MassMutual, one of many greatest US life assurers, mentioned a “small quantity” of its policyholders had been affected and that it had “paused” its pilot because of this.

“We’re conscious that Grail proactively reached out to all our individuals to handle this situation as rapidly as attainable,” it mentioned.

Principal, one other massive US life assurer that has prospects affected by the error, mentioned it was reviewing its relationship with Grail following the incident.

The episode underlines the dangers for insurers in adopting early-detection applied sciences, which provide the prospect of decreasing the quantity paid out in claims by preserving prospects more healthy.

Grail, which is a subsidiary of the world’s greatest gene sequencing firm Illumina, is promoting Galleri at about $950 per take a look at and advertising and marketing it to insurers and enormous employers. The take a look at scans so-called cell-free DNA for modifications brought on by most cancers cells.

The take a look at has been hailed as “revolutionary” and “leading edge” by British and US well being chiefs, though many consultants have urged warning in introducing them earlier than large-scale medical trials show they’ll save lives.

Grail mentioned the faulty letters have been by no means associated to or brought on by an incorrect Galleri laboratory take a look at consequence. The letters have been inadvertently triggered by a PWNHealth software program configuration situation, which had now been disabled, it mentioned in an announcement.

PWNHealth mentioned it had promptly launched an investigation and addressed the underlying downside inside an hour of turning into conscious of it and that it had applied processes to make sure it didn’t occur once more.

“In partnership with Grail, we began contacting impacted people inside 36 hours,” it added.

Grail, which is because of make a presentation on Galleri this weekend on the greatest most cancers convention within the US, mentioned greater than half of people who obtained the letters had not but had their blood drawn for the Galleri take a look at.

“No affected person well being info has been disclosed or breached resulting from this situation, and no affected person hurt or adversarial occasions have been reported,” the corporate mentioned.

In February, US life insurance coverage firm John Hancock introduced it could broaden entry to Grail’s “first-of-a-kind” take a look at, saying preventive care and early detection was important to its dedication to assist prospects dwell “longer, more healthy, higher lives.” It collaborated with Munich Re on the pilot introduced in September.

A spokesperson for John Hancock mentioned its partnership with Grail had not modified. Munich Re declined to remark.

PWNHealth, which is a subsidiary of Everlywell, a digital well being firm, is an impartial telemedicine vendor which evaluations Galleri take a look at requests, prescribes the take a look at and delivers outcomes to sufferers.

© 2023 The Financial Times Ltd. All rights reserved. To not be redistributed, copied, or modified in any manner.